NRDC licences Anti-Arthritis Drug developed by CSIR-NEIST and CCRAS to Kudos Laboratories India
New delhi . License Agreements for commercialization of Anti-Arthritis Drugs (Ointment and Tablets) an ayurvedic formulation to get victory over Joint Pain developed by CSIR-NEIST, Jorhat (for ointment) under Ministry of Science and Technology, Govt. of India and Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi (for the tablets), apex organization for research in Ayurveda in India under the Ministry of AYUSH, Govt. of India were signed and exchanged between Dr. H. Purushotham Chairman & Managing Director, National Research Development Corporation, an Enterprise of the Department of Scientific & Industrial Research, Ministry of Science & Technology, Govt. of India, New Delhi (NRDC) and Shri Karan Goomar, Proprietor, M/s Kudos Labortories India, New Delhi at NRDC Office in the presence of Sh. Gian Chand Goomar, Dr. Priyanka & other Kudos officials and Senior Executives of NRDC were also present during signing ceremony. On this occasion Dr. H. Purushotham explained the benefits of the drugs.
The ointment as well as the tablets are clinically tested and prepared by highest quality natural botanical extracts and there would be no side effects. It is cost effective and to be used by those people who are suffering from Joint Pains.
Kudos is the first licensee for the above two innovative technologies. Now Kudos Labortories India could commcercialize this product under their trade name with due acknowledgement to CSIE-NEIST and CCRAS, Ministry of AYUSH, Government of India.
Read Also : KRDCL, RVNL JV emerges as the Lowest Bidder from Southern RailwayNews Must Read
- Hon’ble Vice President of India Confers `Outstanding PSU of the Year’ Award on HAL
- BharatPe Launches India’s first All-in-One Payment Device
- NBCC registers historical Performance in FY2023-24
- RuPay Unveils Link it, Forget it Campaign at IPL 2024 to Promote RuPay Credit Card on UPI
- NTPC Green Energy Limited Inks MoU with Indus Towers Limited
- CIL’s capex up 6.5% to highest Rs.19,840 Crores in FY 2024
- SCOPE presents SCOPE PREMIER LEAGUE
- MCL Ib Valley Washery commenced commercial operation
- HAL bags Rs 65,000 Cr tender by Defence Ministry
- PSBs' growth output superseded Private Lending firms